Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies

Elena Molokanova; Mark Mercola; Alex Savchenko

doi:10.1016/j.drudis.2017.01.015

Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies

Drug Discov Today. 2017 Jul;22(7):1045-1055. doi: 10.1016/j.drudis.2017.01.015. Epub 2017 Feb 4.

Authors

Elena Molokanova¹, Mark Mercola², Alex Savchenko³

Affiliations

¹ Nanotools Bioscience, Encinitas, CA 92024, USA; Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
² Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA 92037, USA; Department of Medicine and Cardiovascular Institute, Stanford University, Palo Alto, CA 94304, USA.
³ Department of Medicine and Cardiovascular Institute, Stanford University, Palo Alto, CA 94304, USA; Department of Pediatrics, University of California-San Diego, La Jolla, CA 92093, USA. Electronic address: [email protected].

Abstract

The current mandate for the drug discovery industry is to develop more efficient drugs faster while reducing the costs associated with their development. Incorporation of cell stimulation technologies during screening assays is expected to revolutionize the discovery of novel drugs as well as safety pharmacology. In this review, we highlight 'classical' and emerging cell stimulation technologies that provide the ability to evaluate the effects of drug candidates on cells in different functional states to assess clinically relevant phenotypes.

Publication types

Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Cell Physiological Phenomena
Drug Discovery*
Humans
Stimulation, Chemical

Abstract

Publication types

MeSH terms

Grants and funding